Avatrombopag is licensed for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
|NCPE Assessment Process||Complete|
|Rapid review commissioned||16/12/2020|
|Rapid review completed||15/02/2021|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that avatrombopag not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.